Trending...
- Patrick Aloni Joins Historic Gold and Copper Discovery in Argentina with Multimillion-Dollar Stake
- Integris Composites Joins Paris Air Show at USA Pavilion
- Juneau: Registration for Start Smart Soccer opens June 23
EXCELSIOR, Minn. - AkGlobe -- NeuraWorx Medical Technologies, Inc., a neurotechnology therapeutics company, announced today a partnership with prominent neuroscience venture builder and fund, Corundum Neuroscience. As part of the collaboration, Corundum will provide resources, including the initial investment in a NeuraWorx seed funding round, aimed at advancing product development and initiating a clinical feasibility study to explore the efficacy and safety of its Cerebrovascular Pacing SystemTM novel technology.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
More on AkGlobe News
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
More on AkGlobe News
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
More on AkGlobe News
- purelyIV Blog Named One of the Top 45 IV Therapy Blogs by Feedspot
- purelyIV Launches Mobile Iron Infusion Therapy for Patients with Iron Deficiency Anemia
- Smile Makers Dental Care Introduces FP1: East Bay's First Robotic-Assisted Full-Arch Implant Solution for Natural, Fixed Smiles
- DCAS College opens new Representative Office in Malaysian Capital Kuala Lumpur
- GMO Miner: Creating a simple, efficient and reliable new cloud mining experience
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
More on AkGlobe News
- DOT Miners launches a new cloud mining platform: low threshold, high transparency, and helps promote the inclusion of global digital assets
- Fray Fitness and Truemed Partner to Enable HSA/FSA-Funded Fitness Equipment Purchases
- Crazy Discount Codes App Transforms Mobile Shopping With Real-Time Deals
- Sploot Vets and DeepScan Launch Exclusive Regional U.S. Partnership to Bring Breakthrough Pet DNA Test to Market
- As Sober.Buzz Community Explodes It's Growth Globally it is Announcing "Spreading the Good BUZZ" Podcast Hosted by Josh Case Debuting July 7th
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
Source: NeuraWorx Medical Technologies, Inc.
0 Comments
Latest on AkGlobe News
- Juneau: Juneteenth holiday closures at CBJ
- PUSHERMAN- – Best Feature Documentary Official Winner at NYC and London Festivals
- Female Motorsports Sponsorship & Expansion; Acquisition Agreement of UAE-Based Sports Incubator by Online Lottery & Sports Game Provider: Lottery.com
- Global Court Momentum Builds Against Forced Psychiatry; CCHR Urges U.S. Reform
- Integris Composites Joins Paris Air Show at USA Pavilion
- Cheryl Hines' Trailer PROWLING to Sardinia
- Honoring Black History, Culture, and Community in Fall River
- Token-Operated Sake Service Opens at Tobu Nikko Station
- Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
- DivX Enhances AVI Playback Resources; Simplifies Guide to Playing AVI Files with DivX Software
- Patrick Aloni Joins Historic Gold and Copper Discovery in Argentina with Multimillion-Dollar Stake
- Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures
- Goldstar Rehabilitation Celebrates 15 Years of Early Intervention Across Southeastern PA
- United States Congressional Candidate Peter Coe Verbica Unveils 25-Point Federal Plan to Help Make California Affordable Again
- D8Averse Launches D8Acapture: Disruptive Mobile-First App Transforms Utility Pole Data Collection
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
- Mauro Schnaidman named as Managing Director in Miami, Florida
- Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
- Anern Shines at SOLAR AFRICA Kenya with Solar Lithium Battery Storage Technology
- Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague